Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Research & Development (2016 - 2025)

Anaptysbio (ANAB) has disclosed Research & Development for 10 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 39.99% year-over-year to $25.6 million, compared with a TTM value of $136.0 million through Dec 2025, down 17.01%, and an annual FY2025 reading of $136.0 million, down 17.01% over the prior year.
  • Research & Development was $25.6 million for Q4 2025 at Anaptysbio, down from $31.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $42.6 million in Q4 2024 and bottomed at $20.8 million in Q2 2022.
  • Average Research & Development over 5 years is $31.0 million, with a median of $31.1 million recorded in 2023.
  • The sharpest move saw Research & Development soared 57.95% in 2023, then tumbled 39.99% in 2025.
  • Year by year, Research & Development stood at $26.8 million in 2021, then dropped by 12.71% to $23.4 million in 2022, then skyrocketed by 43.43% to $33.5 million in 2023, then increased by 27.04% to $42.6 million in 2024, then tumbled by 39.99% to $25.6 million in 2025.
  • Business Quant data shows Research & Development for ANAB at $25.6 million in Q4 2025, $31.4 million in Q3 2025, and $37.8 million in Q2 2025.